The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predicting response to durvalumab and olaparib in mTNBC using a novel PD-L1 expression biomarker: A comparison with PD-L1 IHC.
 
Ranit Aharonov
Employment - Pangaea Biotech
Leadership - Pangaea Biotech
Stock and Other Ownership Interests - Pangaea Biotech
 
Yaron Kinar
Employment - Pangaea Biotech
Stock and Other Ownership Interests - Pangaea Biotech
 
Gal Dinstag
Employment - Pangaea Biotech
Stock and Other Ownership Interests - Pangaea Biotech
 
Omer Tirosh
Employment - Pangaea Biotech
Stock and Other Ownership Interests - Pangaea Biotech
 
Doreen Ben-Zvi
Employment - Pangaea Biotech
Stock and Other Ownership Interests - Pangaea Biotech
 
Tuvik Beker
Employment - Pangaea Biotech
Leadership - MedAware; Pangaea Biotech
Stock and Other Ownership Interests - MedAware; Pangaea Biotech
Patents, Royalties, Other Intellectual Property - Patents and pending patents assigned to MedAware and Pangea
 
Gordon Mills
Stock and Other Ownership Interests - Bluedot; Catena; ImmunoMET; Nuvectis Pharma; SignalChem; Tarveda Therapeutics; Turbine
Honoraria - Amphista Therapeutics; Astex Pharmaceuticals; AstraZeneca; BlueDot; Chrysalis biotherapeutics; Ellipses Pharma; GlaxoSmithKline; ImmunoMET; Infinity Pharmaceuticals; Ionis Pharmaceuticals; Leapfrog Bio; Lilly; MedaCorp; NanoString Technologies; Nuvectis Pharma; PDX Pharmacy; Qureator; Roche; SignalChem; Symphogen; Tarveda Therapeutics; Turbine; Zentalis
Consulting or Advisory Role - Amphista Therapeutics; Astex Pharmaceuticals; AstraZeneca; BlueDot; Chrysalis biotherapeutics; Ellipses Pharma; GlaxoSmithKline; ImmunoMET; Infinity Pharmaceuticals; Ionis Pharmaceuticals; Leapfrog Bio; Lilly; MedaCorp; NanoString Technologies; Nuvectis Pharma; PDX Pharmacy; Qureator; Roche; SignalChem; Symphogen; Tarveda Therapeutics; Turbine; Zentalis
Research Funding - Adelson Medical Research Foundation; AstraZeneca; Breast Cancer Research Foundation; Genentech; GlaxoSmithKline; ImmunoMET; Komipharm; Lilly; NanoString Technologies; Ovarian Cancer Research Foundation; Prospect Creek Foundation
Patents, Royalties, Other Intellectual Property - DSP technology patent with Nanostring; HRD assay to Myriad Genetics
Travel, Accommodations, Expenses - AstraZeneca; Chrysalis Biomedical Advisors; ImmunoMET; Michigan Primary Care Consortium; Pfizer; Symphogen
 
SMMART Clinical Trials Program
No Relationships to Disclose